Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor re...
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Preclinical studies to date demonstrate that PEGâ[euro][per thousand]sTNF-RI is efficacious in rodent 2-4 and primate 5 models of acute and chronic inflammatory diseases, includingE coli induced septic shock. 6 PEGâ[euro][per thousand]sTNF-RI has demonstrated efficacy in predictive animal models of RA at doses as low as 0.3 mg/kg every other day....
Alternative Titles
Full title
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1766629
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1766629
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/ard.59.suppl_1.i41
